Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CEO INTERVIEW: THOMAS OKARMA - GERON CORPORATION (GERN).


(PAL201) THOMAS OKARMA - GERON CORPORATION (GERN v. t. 1. To grin or yawn. ). Describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward. Sector: Biotechnology. Published date 6/2/02. Tickers featured: GERN. Complete text approximately 3000 words. Document # PAL201.

CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  INTERVIEWS, The Wall Street Transcript, 67 Wall Street, NY 10005. Voice (212) 952 7433. Fax: (212) 668-9842. E-mail: transcript@twst.com.

***
COPYRIGHT 2002 Wall Street Transcript Corporation
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:CEO INTERVIEW: THOMAS OKARMA - GERON CORPORATION (GERN).(Brief Article)
Publication:Wall Street Transcript Digest
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 10, 2002
Words:88
Previous Article:CEO INTERVIEW: RICHARD THOMPSON - ARADIGM CORPORATION (ARDM).
Next Article:[0] CEO INTERVIEW: IAN SMITH - VERTEX PHARMACEUTICALS INC (VRTX).
Topics:



Related Articles
Geron Corporation President/CEO Interviews On RadioWallStreet.com.
GERON REGAINS RIGHTS FOR TELOMERASE INHIBITORS.
CEO INTERVIEW: THOMAS OKARMA - GERON CORPORATION (GERN).
Geron Corporation to Present At Needham & Company 1st Annual Biotech Conference.
HESC-DERIVED HEMATOPOIETIC CELLS PREVENT IMMUNE REJECTION.
CEO INTERVIEW: DAVID GREENWOOD - GERON CORPORATION (GERN).
GERON LICENSES MAXCYTE CELL LOADING TECHNOLOGY.
FDA Allows Trial of Human Stem Cells.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles